Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906655 · ClinicalTrials.gov registry record · Phase 2
An Open Label Study for Palmar Hyperhydrosis
A Phase 2 study of Skin Diseases and Hyperhidrosis, sponsored by Pariser, Robert J., M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT04906655 is a Phase 2 study of Skin Diseases and Hyperhidrosis that has completed, run by Pariser, Robert J., M.D.. The registered enrollment target is 120 participants, below the 201-participant average among 14 other Skin Diseases trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04906655, a Phase 2 study of Skin Diseases and Hyperhidrosis, has completed, sponsored by Pariser, Robert J., M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this open-label study is to evaluate the efficacy and safety of different methods of application of glycopyrronium cloth, 2.4% in patients with palmar hyperhidrosis
Conditions Studied
Interventions
- DRUG Glycopyrronium 2.4 % Medicated Cloth
Study Locations (1)
Virginia
- Virginia Clinical Research, Inc. - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2021-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04906655
The ClinicalTrials.gov registry entry for NCT04906655 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 14 other Skin Diseases trials with a reported enrollment target (40% lower). The listed sponsor is Pariser, Robert J., M.D., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Skin Diseases appearing as the primary indexed condition, and to 1 intervention - of which Glycopyrronium 2.4 % Medicated Cloth is the first listed.
NCT04906655 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04906655 about?
NCT04906655 is a clinical study titled "An Open Label Study for Palmar Hyperhydrosis". The purpose of this open-label study is to evaluate the efficacy and safety of different methods of application of glycopyrronium cloth, 2.4% in patients with palmar hyperhidrosis
What is the current status of trial NCT04906655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2020-10-01. Estimated completion is 2021-05-20.
What conditions does trial NCT04906655 study?
This clinical trial studies the following conditions: Skin Diseases, Hyperhidrosis, Palmar Hyperhidrosis, Sweat Gland Diseases.
What interventions are being tested in trial NCT04906655?
The interventions under investigation include: Glycopyrronium 2.4 % Medicated Cloth (DRUG).
Who is sponsoring clinical trial NCT04906655?
This trial is sponsored by Pariser, Robert J., M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04906655 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
RECRUITING · Phase 2
-
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.